Tag: M.W:100-200

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33454-82-9,Lithium trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

Preparation 4: Ethyl Z-5-methyl-3-(trifluoromethylsulfonyloxy)-2-hexenoateA 20L jacketed reactor was charged with DCM (2.45L), ethyl 3-oxo-5- methylhexanoate (163.3g; 1 eq) and lithiunn triflate (295.86g; 2eq) under an inert atmosphere. The resulting white suspension was stirred and cooled to 0C. N, N- Diisopropylethylamine (134.8g; 182ml; 1 .1 eq) was added over 10 minutes at <10C. The suspension was stirred for 20 minutes at 0C, then triflic anhydride (294.28g; 175ml; 1 .1 eq) was added slowly to the mixture over 30 minutes at <10C. The suspension was stirred at 0C for 1 hour.A sample of the reaction mixture was taken and partitioned between MTBE and sat. NH4CI (1 ml each). The aqueous layer was extracted with MTBE (1 ml) and the combined organic extracts were filtered through cotton wool/MgSO . Analysis by GC indicated that less than 2% starting material remained.The mixture was allowed to warm from 0 to 25C over 1 hr whilst quenching with sat. NH4CI (980ml). DCM (490ml) was added and the mixture was stirred for 5 minutes, then allowed to settle and the layers were separated. The aqueous layer was extracted with DCM (490ml). The combined organic phases were then washed with 1 M HCI (2 490ml), water (490ml) and 20% brine (490ml), then stirred for 30 minutes with MgSO4 (~165g) for 15-30 minutes. The solids were removed by filtration and washed with DCM (165ml). The filtrate was concentrated under vacuum at <40C to give an orange/brown oil containing crystalline solids. The crude product was triturated with MTBE (980ml). The mixture was filtered and the solids were washed with MTBE (2 x 165ml). The filtrate was concentrated under vacuum at <40C to give the title product as an orange/brown oil: overall yield 271 g (94%; corrected for 2.1 %w/w MTBE content); 87.7% area purity by GC. 1 H NMR (CDCI3, delta= 7.20): delta 0.94 (6H, d, J = 6.7 Hz), 1 .24 (3H, t, J = 7.2 Hz), 1 .89 (1 H, hept, J = 6.8 Hz), 2.17 (2H, d, J = 7.2 Hz), 4.18 (2H, q, J = 7.2 Hz), 5.67 (1 H, s) ppm., 33454-82-9

As the paragraph descriping shows that 33454-82-9 is playing an increasingly important role.

Reference£º
Patent; PFIZER MANUFACTURING IRELAND; BURRELL, Adam James Musgrave; MARTINEZ, Carlos Alberto; MCDAID, Paul Oliver; O’NEILL, Padraig Mary; WONG, John Wing; WO2012/25861; (2012); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

7328-91-8, 2,2-Dimethylpropane-1,3-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

N1-(5-chloro-4-(1-(phenylsulfonyl)-1H-indol-3-yl)pyrimidin-2-yl)-2,2-dimethylpropane-1,3-diamineA suspension of 3-(2,5-dichloropyrimidin-4-yl)-l-(phenylsulfonyl)-1H-indole (0.590g, 1.46mmol), 3,3-dimethylaminopropyldiamine (149mg, 1.46mmol) in EtOH/DMF (4: 1, lOmL) was heated at 130¡ãC (mW) for 20min. The mixture was diluted with EtOAc (30mL), washed with sat. NaHC03 (5mL), brine (5mL) dried (MgS04), filtered and concentrated under reduced pressure to afford the title compound (600mg, 1.28mmol, 87percent) as a white solid which was used in the next step without any further purification.

7328-91-8, The synthetic route of 7328-91-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SYROS PHARMACEUTICALS, INC.; PARAZA PHARMA, INC.; CIBLAT, Stephane; DEROY, Patrick; LEBLANC, Melissa; MARINEAU, Jason, J.; MOORE, Joel; ROY, Stephanie; SIDDIQUI, M., Arshad; SPROTT, Kevin; WINTER, Dana, K.; KABRO, Anzheliika; LEGER, Serge; MILLER, Tom; SCHMIDT, Darby; BRADLEY, Michael; WO2015/58163; (2015); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

7328-91-8, 2,2-Dimethylpropane-1,3-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Pyridine-2-carbaldehyde (30 mmol, 3.21 g)And 2,2-dimethyl-1,3-propanediamine (15 mmol, 1.53 g)30mL of methanol mixed,After 7.0 hours at room temperature,Slowly add NaBH4 (120 mmol, 4.54 g) slowly while stirring in an ice-water bath Slowly warmed to 70 for 5 hours.Stop the reaction,Cool to room temperature,Rotate the reaction solution.Then 50mL CH2Cl2 dissolved, filtered, Filtrate spin dry,Have yellow oily sticky substance.After dissolving the above yellow oily dope in 30 mL of methanol,To this was added an equimolar amount of aqueous formaldehyde solution,After stirring at room temperature for 3 hours,The solvent was removed under reduced pressure,Isolated and purified by column chromatography to give 3,3-dimethyl-1,3-bis (2-picolyl) hexahydropyrimidine (3.96 g, yield 89percent)., 7328-91-8

Big data shows that 7328-91-8 is playing an increasingly important role.

Reference£º
Patent; Henan University of Technology; Yang Liangru; Mai Wenpeng; Mao Pu; Xiao Yongmei; Yuan Jinwei; Qu Lingbo; (12 pag.)CN104744519; (2017); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1126-58-5,1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride,as a common compound, the synthetic route is as follows.

1126-58-5, General procedure: To a magnetically stirred solution of substituted isatin (5mmol) in 7ml of absolute ethanol, a corresponding pyridinium acetohydrazide (5mmol) and three drops of trifluoroacetic acid were successively added. The reaction mixture was heated under reflux for 3h. After spontaneously cooling the solution to room temperature, the precipitate formed was filtered, washed with absolute ether and dried in vacuo.

1126-58-5 1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride 70773, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Bogdanov, Andrei V.; Zaripova, Ilyuza F.; Voloshina, Alexandra D.; Sapunova, Anastasia S.; Kulik, Natalia V.; Tsivunina, Irina V.; Dobrynin, Alexey B.; Mironov, Vladimir F.; Journal of Fluorine Chemistry; vol. 227; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1126-58-5,1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride,as a common compound, the synthetic route is as follows.

General procedure: To a mixture of the corresponding bis(isatin) 1-8 (5 mmol) and Girard?s reagent (2.5 mmol) in 7 mL of absolute ethanol were added three drops of trifluoroacetic acid. The reaction mixture was refluxed for 2 h. After spontaneous cooling of the solution to room temperature, the formed precipitate was filtered off, washed with absolute diethyl ether and dried in vacuum (12 mmHg)., 1126-58-5

As the paragraph descriping shows that 1126-58-5 is playing an increasingly important role.

Reference£º
Article; Bogdanov; Zaripova; Mustafina; Voloshina; Sapunova; Kulik; Mironov; Russian Journal of General Chemistry; vol. 89; 7; (2019); p. 1368 – 1376; Zh. Obshch. Khim.; vol. 89; 7; (2019); p. 1004 – 1012,9;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

63-68-3, H-Met-OH is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

L-Methionine (0.5 g, 1 equivalent) was suspended in methanol (30 ml C=0.1M) in a 100 ml flask equipped with a magnetic stirrer and placed under nitrogen. Thionyl chloride (0.5 ml, 2 equivalents) was added to the solution dropwise at 0 C. then heated under reflux for 16 hours. The reaction mixture was then evaporated to yield a pale yellow solid. The solid was triturated with hot diethyl ether and the solution discarded to leave the title compound 2? a white solid which was further dried under vacuum. (0.65561 g, 98% yield). [0377] 1H NMR (D2O, 500 MHz) deltaH: 4.24 (1H, m, 3) 3.79 (3H, s, 1), 2.63 (2H, t, 5), 2.25 (1H, m, 4), 2.16 (1H, m, 4), 2.06 (1H, s, 6) [0378] 13C NMR (D2O, 125 MHz) deltac: 170.58 (2), 53.64 (1), 51.70 (3), 28.71 (4), 28.41 (5), 13.85 (6). [0379] IR (neat, vmax, cm-1): 2880.8/2676.2 (CH3, CH2, CH), 2016.2, 1742.2 (C?O, ester), 1483.6, 1443.5, 1227+1194.7+1149.8+1079.5 (C-O). [0380] HRMS m/z (+ESI): C6H14NO2S, mass found=164.074 (Error=0.071 ppm), 63-68-3

The synthetic route of 63-68-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; The University of Sussex; Viseux, Eddy Michel Elie; Gallop, Christopher; Bobin, Mariusz; US2014/39200; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10581-12-1, Tetramethylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 2 In a round flask, 2 mL of methyl cyanide (acetonitrile) as an organic solvent was introduced, 0.145 g (1 mmol) of 5-chloromethylfurfural (CMF, compound I) was dissolved in the organic solvent, 0.133 g (1 mmol) of tetramethylammonium acetate was added to the solution, and then the mixed solution was reacted at normal pressure and room temperature for 5 minutes. After the reaction, the reaction product was extracted by the addition of a small amount of water (5 mL) and ethyl acetate (added twice by 20 mL) to obtain an organic layer. The obtained organic layer was concentrated under reduced pressure to obtain light yellow liquid 5-acetoxymethylfurfural (AcHMF, compound II). The yield thereof is 95%. It was ascertained by 1H-NMR that the light yellow liquid is a target material. Analysis data is as follows. AcHMF: 1H NMR (400 MHz, CDCl3) 9.65 (s, 1H), 7.25 (d, J=3.6, 1H), 6.62 (d, J=3.6, 1H), 5.13 (s, 2H), 2.12 (s, 3H)

10581-12-1, 10581-12-1 Tetramethylammonium acetate 82741, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Kim, Baek Jin; Cho, Jin Ku; Kim, Sangyong; Lee, Do Hoon; Kim, Young Gyu; Kang, Eun-Sil; Hong, Yeon-Woo; Chae, Da Won; US2015/51413; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10581-12-1, Tetramethylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

10581-12-1, General procedure: The appropriate ligand (H3LR)(0.18 mmol, R=OMe, Me H, Cl, Br), was deprotonated with 3.1 molar equiv. KH in3mL of DMA in a 25-50-mL round bottom flask. After H2 evolution ceased (?5-10 min), an excess 1.2 eq of Mn(OAc)2 was added along with 1mL of DMA andstirred for 30 min. Then 2.1 equivalents of [Me4N][OAc] were added along with 1mL ofDMA and the reaction was stirred at room temperature overnight. The mixture was filteredthrough a glass fritted funnel to remove insoluble material. The filtrate was layeredunder Et2O and allowed to stand for recrystallization. In most cases a whitecrystalline solid was obtained and isolated by filtration. In some cases, an oily residuewas obtained that through trituration with Et2O and scraping yields a white solid. Ineither case, the solids from DMA/Et2O was then redissolved in acetonitrile and filteredto remove insoluble material. Recrystallization was accomplished by slow vapor diffusionof Et2O into acetonitrile. The solids obtained were washed with diethyl ether anddried under vacuum. See below for characterization data for the remainingMn(II) complexes.

10581-12-1 Tetramethylammonium acetate 82741, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Cannella, Anthony F.; Surendhran, Roshaan; MacMillan, Samantha N.; Gupta, Rupal; Lacy, David C.; Journal of Coordination Chemistry; vol. 72; 8; (2019); p. 1287 – 1297;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4045-44-7,1,2,3,4,5-Pentamethylcyclopenta-1,3-diene,as a common compound, the synthetic route is as follows.

Under an argon atmosphere the excess of 1,2,3,4,5-pentamethylcyclopentadiene(19 mL, 0.167 mmol) was added to the suspensionof [(C8H14)2RhCl]2 (30 mg, 0.084 mmol) in C2H4Cl2 (1 ml).The reaction mixture was stirred overnight at room temperature.Then, the excess of NaHCO3 (84 mg, 1.00 mmol) was added and themixture was cooled to 0 C in an ice bath. The solution of bromine(135 mg, 43 mL, 0.84 mmol) in C2H4Cl2 (0.5 ml)was added dropwise.After the addition, the reaction mixture was stirred for another30 min at 0 C. The mixture was then opened to air and filtered, theprecipitate was washed with C2H4Cl2 (4 1 ml) and the combinedsolution was evaporated in vacuum. The precipitate (presumably[Cp*RhBr3]n) was washed with Et2O (32 ml) and dried in vacuum(20 mg, 50%). The obtained precipitate was suspended in hot C2H4Cl2 (3 ml)and ethylene was bubbled through until the complete dissolutionof the precipitate. The mixture was evaporated to dryness in vacuum.The residue was dissolved in CHCl3 (1 ml) and the product 3was precipitated by Et2O (5 ml) as red powder, which was dried invacuum (16 mg, 94%).1H NMR (400 MHz, CDCl3): delta 1.73 (s, 15H). 13C NMR (101 MHz,CDCl3): delta 94.98 (d, JRh-C 8.8 Hz), 10.15. Anal. Calc. forC10H15RhBr2: C 30.18, H 3.80; found: C 30.58, H 3.98., 4045-44-7

As the paragraph descriping shows that 4045-44-7 is playing an increasingly important role.

Reference£º
Article; Pototskiy, Roman A.; Lisov, Alexey A.; Nelyubina, Yulia V.; Perekalin, Dmitry S.; Journal of Organometallic Chemistry; vol. 862; (2018); p. 71 – 75;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13910-48-0,N1-Benzylpropane-1,3-diamine,as a common compound, the synthetic route is as follows.

c) methyl [(4Z)-4-(4-benzyl-l,4-diazepan-2-ylidene)-l-(2-chlorophenyl)-5-oxo-4,5- dihydro-lH-pyrazol-3-yl] acetate Compound of Formula (II), Scheme 1)To a solution of the above obtained methyl [4-(chloroacetyl)-l-(2-chlorophenyl)-5- hydroxy-lH-pyrazol-3-yl]acetate (Compound of Formula (V), 1.88 mmol, 1 eq.) in 3 mL of acetonitrile was added, slowly at zero degree Celsius, N-benzylpropane-l ,3-diamine (0.277 mg, 0.9 eq.). The reaction mixture was stirred at 0C for 0.5 h. The resulting solution was purified by silica plug using ethylacetate/0.1% triethylamine. The solvent was evaporated in vacuo and allowed to isolate a red solid which proved to be the pure methyl [(4Z)-4-(4- benzyl-l,4-diazepan-2-ylidene)-l-(2-chlorophenyl)-5-oxo-4,5-dihydro-lH-pyrazol-3-yl] acetate (0.530 g). Yield 71 %. MS(ESI+): 454.0., 13910-48-0

13910-48-0 N1-Benzylpropane-1,3-diamine 83811, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; GENKYOTEX SA; PAGE, Patrick; GAGGINI, Francesca; LALEU, Benoit; WO2011/36651; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI